2015•Journal for ImmunoTherapy of CancerOpen access

Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab

Yoshinobu Koguchi, Helena Maria Hoen, Shelly Bambina, Michael D. Rynning, Richard K. Fuerstenberg, Zipei Feng, Bernard A. Fox, Carlo Bruno Bifulco, Brendan D. Curti, Walter John Urba, Christina M. Milburn, Alan J. Korman, Keith S. Bahjat

Open full text 4 citations

Abstract

Meeting abstracts Treatment with ipilimumab improves overall survival (OS) in patients with metastatic melanoma. Because ipilimumab targets T lymphocytes and not the tumor itself, efficacy may be uniquely sensitive to immunomodulatory factors present at the time of treatment. We analyzed serum

Open-access reader

About this research paper

What this paper is about

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Ipilimumab, Metastatic melanoma, Medicine, Melanoma, Oncology, Overall survival, Internal medicine, Immunotherapy